<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The goal of this study was to evaluate routine flow cytometric (FC) immunophenotypic markers in differentiating between Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and CD10+ diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We performed retrospective analysis of FC data from 55 patients </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated 9 FC parameters: forward and side scatter (FSC and SSC); mean fluorescent intensity (MFI) for CD20, CD10, CD38, CD79b, CD43, and CD71; and the percentage of neoplastic cells positive for CD71 (%CD71) </plain></SENT>
<SENT sid="3" pm="."><plain>The FSC; MFIs of CD10, CD43, CD79b, and CD71; and %CD71 cells were significantly different between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and CD10+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (P &lt; .05; Student t test) </plain></SENT>
<SENT sid="4" pm="."><plain>A 5-point scoring system (FSC, %CD71, and MFIs of CD43, CD79b, and CD71) was devised, and 6 (60%) of 10 BLs scored 3 or greater and 1 (10%) of 10 CD10+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> scored 3 (P = .04; Ï‡(2)) </plain></SENT>
<SENT sid="5" pm="."><plain>Our findings indicate that routine FC parameters can aid in differentiating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> from CD10+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
</text></document>